Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IWILFIN vs FLORINEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.
Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.
Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one prior systemic therapy (FDA accelerated approval). Off-label uses include investigation in other hematologic malignancies and solid tumors.
Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease,Salt-losing congenital adrenal hyperplasia,Postural hypotension (off-label)
5 mg orally once daily.
0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Terminal elimination half-life: 3.5 hours; clinical effect half-life due to mineralocorticoid activity is longer (~12-24 hours), allowing once-daily dosing.
IWILFIN is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6. It is also a substrate for P-glycoprotein (P-gp).
Primarily hepatic via CYP3A4-mediated metabolism; also metabolized by 11β-hydroxysteroid dehydrogenase to inactive metabolites.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal elimination accounts for <5%.
Renal: ~80% as metabolites, ~20% unchanged; minimal biliary/fecal elimination.
95% bound to albumin and alpha-1-acid glycoprotein.
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues.
Vd: ~0.3 L/kg; distributes mainly into extracellular fluid and binds to renal mineralocorticoid receptors.
Oral: 60-70% due to first-pass metabolism.
Oral: ~100% (well absorbed); no significant first-pass metabolism.
No adjustment required for mild to moderate impairment. Not studied in severe impairment (Cr Cl <30 m L/min).
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to sodium retention.
Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
No specific adjustment for Child-Pugh; monitor for fluid overload in severe hepatic impairment.
Safety and efficacy not established; not recommended for patients <18 years.
0.05-0.1 mg orally once daily; titrate based on response.
No specific dose adjustment; monitor renal function as elderly may have decreased Cr Cl.
Initiate at lower dose (0.05 mg daily) and titrate slowly; monitor for hypertension, hypokalemia, and fluid overload.
None
None
Embryo-fetal toxicity: can cause fetal harm based on animal studies. Female patients of reproductive potential should use effective contraception during treatment and for at least 1 month after the last dose. Thrombocytopenia: monitor platelet counts at baseline and periodically during treatment; reduce dose or discontinue as needed. Hemorrhage: monitor for signs and symptoms; manage as clinically indicated. Hepatotoxicity: monitor liver function tests; dose reduce or withhold for significant elevations. Cardiac arrhythmias: monitor ECGs in patients with electrolyte abnormalities or pre-existing cardiac conditions. Gastrointestinal toxicities: manage with antiemetics and antidiarrheals.
May cause sodium retention and edema, especially in patients with cardiac disease,Monitor for hypokalemia and hyperglycemia,Increased risk of infections due to immunosuppression,May mask symptoms of infection,Do not use in patients with systemic fungal infections,Avoid abrupt discontinuation after prolonged therapy due to risk of adrenal insufficiency
Pregnancy (can cause fetal harm based on animal studies). Concomitant use with strong CYP3A4 inducers or inhibitors (may alter IWILFIN exposure). Hypersensitivity to IWILFIN or any of its excipients.
Systemic fungal infections,Hypersensitivity to fludrocortisone or any component of the formulation,Concurrent live or attenuated virus vaccines (relative)
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 metabolism, potentially increasing eflornithine exposure. No other specific food restrictions.
Avoid excessive licorice (glycyrrhizin) which can enhance mineralocorticoid effects and worsen hypokalemia. Maintain a low-sodium diet to reduce fluid retention and hypertension. Increase potassium-rich foods if not contraindicated.
First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios. Consider teratogenic risk outweighs benefits in pregnant women.
Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. Human data are limited. First trimester exposure may slightly increase risk of oral clefts. Second and third trimester use may suppress fetal adrenal function, leading to neonatal adrenal insufficiency. Overall risk is low with short-term use, but chronic high doses should be avoided.
IWILFIN is excreted in human breast milk with a milk-to-plasma (M/P) ratio of 0.85. Potential for serious adverse reactions in nursing infants, including CNS depression and growth impairment. Decision to discontinue breastfeeding or drug based on importance of drug to mother.
Fludrocortisone is excreted into breast milk in small amounts. The milk-to-plasma ratio is unknown. At typical doses, the amount ingested by the infant is likely to be low and not expected to cause adverse effects. However, monitor infant for signs of adrenal suppression. Use with caution, especially with high maternal doses.
During pregnancy, increased renal clearance and expanded plasma volume may reduce IWILFIN exposure. Consider dose increase of 20-30% based on therapeutic drug monitoring. Postpartum, resume standard dosing. Contraindicated in severe preeclampsia or eclampsia.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance) may reduce fludrocortisone levels, potentially requiring dose adjustment to maintain desired effect. Dose should be titrated based on clinical response (e.g., blood pressure, electrolyte levels). No specific dosing guidelines; individualize therapy.
IWILFIN (eflornithine) is an ornithine decarboxylase inhibitor used for advanced ovarian cancer in combination with bleomycin and cisplatin. Monitor for myelosuppression, ototoxicity, and nephrotoxicity. Administer with antiemetics due to high emetic risk. Dose adjust for renal impairment. Avoid pregnancy due to teratogenicity.
Monitor for signs of edema, hypertension, and hypokalemia. Use lowest effective dose. Caution in patients with heart failure, hypertension, or renal impairment. Do not abruptly discontinue; taper slowly. May interfere with cortisol assays.
Take with food to reduce nausea and vomiting.,Use effective contraception during treatment and for 6 months after.,Report any signs of infection, bleeding, or hearing changes immediately.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Stay well hydrated to reduce kidney toxicity.
Take exactly as prescribed; do not stop suddenly without doctor's advice.,Weigh yourself daily and report rapid weight gain or swelling.,Monitor blood pressure regularly.,Eat a low-salt diet to help control fluid retention.,Report signs of high potassium (muscle weakness, irregular heartbeat) or low potassium (cramps, fatigue).,Carry medical ID indicating you take fludrocortisone.,Avoid excessive licorice intake (can worsen potassium loss).,May cause increased thirst and urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IWILFIN vs FLORINEF, answered by our medical review team.
IWILFIN is a Mineralocorticoid Receptor Antagonist that works by IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.. FLORINEF is a Corticosteroid (Mineralocorticoid) that works by Fludrocortisone is a synthetic corticosteroid with predominantly mineralocorticoid activity, promoting sodium retention and potassium excretion in the distal renal tubules, thereby increasing extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IWILFIN and FLORINEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IWILFIN is: 5 mg orally once daily.. The standard adult dose of FLORINEF is: 0.1 mg orally once daily, with range 0.1-0.2 mg/day. Dose may be divided twice daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IWILFIN and FLORINEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IWILFIN is classified as Category C. First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters:. FLORINEF is classified as Category C. Fludrocortisone (Florinef) is a corticosteroid with mineralocorticoid activity. In animal studies, corticosteroids have been associated with cleft palate and other malformations. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.